Broad-spectrum coverage (aerobes, anaerobes, atypicals such as rickettsiae, chlamydiae, mycoplasmas): Which antibiotic best fits this profile?

Difficulty: Easy

Correct Answer: Tetracycline

Explanation:


Introduction / Context:
Some pathogens lack classic peptidoglycan or live intracellularly (rickettsiae, chlamydiae, mycoplasmas). Tetracyclines are noted for wide coverage including many Gram-positive and Gram-negative bacteria, atypicals, and some anaerobes, making them a hallmark broad-spectrum class.


Given Data / Assumptions:

  • We seek an agent covering aerobic/anaerobic bacteria plus atypicals (rickettsiae, chlamydiae, mycoplasmas).
  • Standard pharmacology profiles are assumed.


Concept / Approach:
Tetracyclines bind the 30S ribosomal subunit and block aminoacyl-tRNA binding, inhibiting protein synthesis. Their intracellular penetration underlies activity against rickettsiae and chlamydiae; activity against mycoplasma reflects ribosomal targeting in the absence of cell walls.


Step-by-Step Solution:
Evaluate candidates: gentamicin (limited anaerobe/atypical coverage); metronidazole (excellent anaerobes/protozoa but weak for aerobes and atypicals listed); vancomycin (Gram-positive only); penicillin G (narrow spectrum). Identify tetracycline as classically covering rickettsiae, chlamydiae, mycoplasmas, and many aerobes; some anaerobic coverage exists depending on agent. Choose tetracycline as best match.


Verification / Alternative check:
Clinical indications such as atypical pneumonia (mycoplasma, chlamydophila), rickettsial diseases (doxycycline), and broad empiric use support this selection.


Why Other Options Are Wrong:
They lack the simultaneous atypical breadth or anaerobic/aerobic balance described.


Common Pitfalls:
Overestimating aminoglycoside coverage of anaerobes (ineffective in low oxygen); assuming metronidazole is broad for all categories (it is not).


Final Answer:
Tetracycline.

More Questions from Antimicrobial Chemotherapeutic Agents

Discussion & Comments

No comments yet. Be the first to comment!
Join Discussion